OMRON (TSE:6645) has drawn attention after a roughly 60% year to date share price gain, putting its factory automation, healthcare, and control systems driven earnings profile alongside a premium P/E of about 28.9x.
Recent trading has been strong, with OMRON's share price delivering a 6.53% 1 month return and a 13.73% 3 month share price gain. This has contributed to a 60.04% year to date move that contrasts with a 5 year total shareholder return that is still down 36.10%.
Scan beyond OMRON's sharp rerating and line up other robotics and automation plays using our curated 91 robotics and automation stocks as a comparison set.
After a 60% year to date surge and a P/E near 29x, OMRON now presents a simple question: Does the current price still offer a reasonable trade off between risk and reward for new buyers?
Price-to-Earnings of 28.9x: Is it justified?
OMRON trades on a P/E of 28.9x against a last close of ¥6,395, which places the stock at a clear premium to much of the Japanese electronics universe.
The P/E ratio compares today's share price to the most recent earnings per share. For a factory automation and healthcare equipment group like OMRON, this metric often reflects how much investors are willing to pay for its earnings profile across industrial automation, data solutions, and medical devices.
That premium comes with mixed signals. Relative to an estimated fair P/E of 22.1x, the current 28.9x looks stretched and suggests the market is paying up beyond what the SWS fair ratio implies the multiple could move toward. In contrast, OMRON's P/E sits well below the peer average of 45.8x for comparable stocks, which indicates the stock is cheaper than many robotics and automation plays despite its higher valuation versus the broader JP Electronic industry average of 16.9x.
Explore the SWS fair ratio for OMRON.
Result: Price-to-Earnings of 28.9x (OVERVALUED)
Still, OMRON's 28.9x P/E and a 5-year total shareholder return down 36.10% leave little room for earnings disappointment or slower automation demand.
Find out about the key risks to this OMRON narrative .
Another View: OMRON Through The SWS DCF Lens
Price based on earnings tells only part of the story. The SWS DCF model, which estimates the value of OMRON using projected future cash flows, suggests a fair value of about ¥4,142 per share against the current ¥6,395 level. That points to an overvalued signal. How much weight do you give to cash flow math compared with headline multiples?
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day ( check out OMRON for example ). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 13 high quality undervalued stocks . If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Mixed signals on OMRON's valuation and track record can pull sentiment in both directions, so move fast, examine the numbers carefully, and weigh the 2 key rewards and 1 important warning sign
Looking for more investment ideas beyond OMRON?
If OMRON has sharpened your focus on quality, do not stop here. Cast the net wider so you are not relying on a single opportunity.
-
Target resilience first and stress test your portfolio against market shocks using a 23 resilient stocks with low risk scores .
-
Hunt for quality at a sensible price and stack potential bargains side by side with a 13 high quality undervalued stocks .
-
Spot tomorrow's quiet success stories early and compare under-the-radar opportunities with a 74 high quality undiscovered gems .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include 6645.T .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
